Stage I testicular cancer

Current Opinion in Urology

Volumn 13, Issue 6, 2003, Pages 473-476

  Scholz, Michael ^a   Höltl, Wolfgang ^a  

^a KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Germ cell tumours; Non seminomatous disease; Risk factors; Seminoma; Treatment options for clinical stage i disease

Indexed keywords

CARBOPLATIN;

CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE SEVERITY; GERM CELL TUMOR; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; PARAAORTIC LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEMINOMA; STANDARD; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; TREATMENT INDICATION;

CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOPLASM STAGING; NEOPLASMS, GERM CELL AND EMBRYONAL; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK FACTORS; SURVIVAL ANALYSIS; TESTICULAR NEOPLASMS;

EID: 0442323415     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200311000-00009     Document Type: Review

References (33)

1. Power DA, Brown RS, Brock CS, et al. Trends in testicular carcinoma in England and Wales, 1971-99. BJU Int 2001; 87:361-365.
2. Sobin LH, Wittekind CH (editors). TNM Classification of malignant tumors. Union Internationale Contre le Cancer, 5th ed. New York: Wiley-Liss; 1997.
3. Klepp OA, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990; 8:509-518.
4. Freedman LS, Parkinson MC, Jones WG, et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchiectomy alone. Lancet 1987; 2:294-298.
5. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992; 10:1762-1768.
6. Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long term results of a prospective trial. Authors update. Classic Papers Curr Comment 2001; 6:356-363.
7. Albers P, Siener R, Kliesch S, et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003; 21:1505-1512. This is the largest prospective trial of the assessment of risk factors in a group of patients who were treated by retroperitoneal lymph node dissection.
8. Spermon JR, Roeleveld TA, Van der Poel CA, et al. Comparison of surveillance and retroperitoneal lymph node dissection in stage I nonseminomatous germ cell tumors. Urology 2002; 59:923-929. This is a nice paper comparing retrospectively the treatment outcome of surveillance and RPLND in two institutions.
9. Roeleveld TA, Horenblas S, Meinhardt W, et al. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 2001; 166:2166-2170.
10. Heidenreich A, Albers P, Hartmann M, et al. Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group Trial. J Urol 2003; 169:1710-1714. This multicentre trial by the German Testicular Cancer Study Groups gives an extensive description of the therapeutic consequences and outcome of patients with clinical stage I NSGCT treated with RPLND.
11. Peckham MJ, Barrett A, Horwich A, Hendry WF. Orchiectomy alone for stage I testicular nonseminoma. Br J Urol 1983; 55:754-759.
12. Sogani PC, Perrotti M, Herr HW, et al. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998; 159:855-858.
13. Gez E, Wygoda M, Nussbaum N, et al. Surveillance in patients with stage I testicular nonseminomatous germ cell tumors. Cancer Invest 1993; 11:10-14.
14. Swanson DA. The case for observation of patients with clinical stage I nonseminomatous germ cell testicular tumors. Semin Urol 1993; 11:92-98.
15. Rorth M, Jacobsen GK, von der Maase H, et al. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. J Clin Oncol 1991; 9:1543-1548.
16. Sturgeon JFG, Jewett MAS, Alison RE, et al. Surveillance after orchiectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 1992; 10:564-568.
17. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10 year follow up. J Urol 1995; 154:1045-1049.
18. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow up: a single center 10 year experience. J Clin Oncol 1995; 13:1188-1194.
19. Germa Lluch JR, Climent MA, Villavicencio H, et al. Treatment of stage I testicular tumours. Br J Urol 1993; 71:473-477.
20. Patel SR, Richardson RL, Kvols L, et al. Observation after orchiectomy in clinical stage I nonseminomatous germ cell tumor of the testis. Am J Clin Oncol 1990; 13:379-381.
21. Sujka SK, Huben RP. Clinical stage I nonseminomatous germ cell tumors of the testis. Urology 1991; 38:29-31.
22. Colls BM, Harvey VJ, Skelton L, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999; 83:76-82.
23. Hendry WF, Norman A, Nicholls J, et al. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 2000; 86:89-93.
24. Studer UE, Burkhard FC, Sonntag RW. Risk-adapted management with adjuvant chemotherapy in patients with high risk clinical stage I nonseminomatous germ cell tumour. J Urol 2000; 163:1785-1787.
25. Cullen MH, Stenning SP, Parkinson MC, et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996; 14:1106-1113.
26. Pont J, Albrecht W, Postner G, et al. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long term results of a prospective trial. J Clin Oncol 1996; 14:441-448.
27. Warde P, Gospodarowicz MK, Banerjee D, et al. Results of a policy of surveillance in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 1993; 27:11-15.
28. von der Maase H, Specht L, Jacobsen GK, et al. Surveillance following orchiectomy for stage I seminoma of the testis. Eur J Cancer 1993; 14:1931-1934.
29. Norwich A, Alsanjari N, A'Hern R, et al. Surveillance following orchidectomy for stage I testicular seminoma. Br J Cancer 1992; 65:775-778.
30. Warde P, Specht L, Norwich A, et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol 2002; 20:4448-4452. This paper presents a pooled analysis of the four largest surveillance series.
31. Horwich A, Oliver R, Wilkinson P, et al. A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. Br J Cancer 2000; 83:1623-1629.
32. Reiter WJ, Brodowicz T, Alavi S, et al. Twelve-year experience with two courses of adjuvant single-agent carboplatin therapy for clinical stage I seminoma. J Clin Oncol 2001; 19:101-104.
33. Dieckmann K-P, Brüggeboes B, Pichlmeier U, et al. Adjuvant treatment of clinical stage I seminoma: Is one single course of carboplatin sufficient? Urology 2000; 55:102-106.